The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Garbuzenko D.V.

South Ural State Medical University

Effectiveness of etiotropic therapy in achieving recompensation of cirrhosis

Authors:

Garbuzenko D.V.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2025;14(2): 68‑77

DOI: 10.17116/dokgastro20251402168

Read: 770 times

Download PDF (RU)
Contact the author
Table of contents

EFFECTIVENESS OF ETIOTROPIC THERAPY IN ACHIEVING RECOMPENSATION OF CIRRHOSIS
EFFECTIVENESS OF ETIOTROPIC THERAPY IN ACHIEVING RECOMPENSATION OF CIRRHOSIS

To cite this article:

Garbuzenko DV. Effectiveness of etiotropic therapy in achieving recompensation of cirrhosis. Russian Journal of Evidence-Based Gastroenterology. 2025;14(2):68‑77. (In Russ.)
https://doi.org/10.17116/dokgastro20251402168

 
Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Hepa­tocellular carcinoma asso­ciated with nona­lcoholic fatty liver disease. P.A. Herzen Journal of Onco­logy. 2024;(6):57-62
Evaluation of periodontal status in patients with liver cirrhosis. Stomatology. 2025;(2):6-10
Abstract:

OBJECTIVE:

To provide an updated review of the effectiveness of etiotropic therapy in achieving recompensation in patients with liver cirrhosis associated with hepatitis B and C viruses (HBV, HCV) and alcohol-related liver disease.

KEY POINTS

The conventional understanding of decompensated cirrhosis as an irreversible stage in its natural course is now being reconsidered. Emerging evidence suggests that eliminating the underlying etiological factor may promote structural and functional hepatic recovery, reduce portal hypertension and its associated complications, and lower the risk of hepatocellular carcinoma. Clinical improvement can also lead to better patient outcomes and, in some cases, allow for the removal of liver transplant candidates from waiting lists. To establish a standardized definition of cirrhosis recompensation, the Baveno VII Consensus Conference introduced specific criteria. These include: elimination of the primary etiological factor; resolution of ascites (without diuretics), hepatic encephalopathy (without lactulose or rifaximin), and the absence of recurrent variceal bleeding for at least 12 months; along with sustained improvement in liver function tests.

Currently, the effectiveness of etiotropic therapy in meeting these criteria has been evaluated only in patients with decompensated cirrhosis due to alcohol-related liver disease and HBV/HCV infection. This is largely due to the limited understanding of the underlying causes of other chronic diffuse liver diseases.

CONCLUSION

Research in this field is still in its early stages. Further studies are needed to clarify the pathophysiological mechanisms, modifying factors, predictors, and potential non-invasive biomarkers of cirrhosis recompensation.

Keywords:

Liver cirrhosis
decompensation
recompensation
viral hepatitis
alcoholic liver disease

Authors:

Garbuzenko D.V.

South Ural State Medical University

Received:

22.10.2024

Accepted:

21.01.2025

Close metadata

References:

  1. D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. Journal of Hepatology. 2018;68(3):563-576.  https://doi.org/10.1016/j.jhep.2017.10.020
  2. Roccarina D, Rosselli M, Genesca J, Tsochatzis EA. Elastography methods for the non-invasive assessment of portal hypertension. Expert Review of Gastroenterology and Hepatology. 2018;12(2):155-164.  https://doi.org/10.1080/17474124.2017.1374852
  3. Jalan R, D’Amico G, Trebicka J, Moreau R, Angeli P, Arroyo V. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. Journal of Hepatology. 2021;75(suppl 1):14-26.  https://doi.org/10.1016/j.jhep.2021.01.018
  4. Tonon M, D’Ambrosio R, Calvino V, Tosetti G, Barone A, Incicco S, Gambino C, Gagliardi R, Borghi M, Zeni N, Piano S, Lampertico P, Angeli P. A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis. Journal of Hepatology. 2024;80(4):603-609.  https://doi.org/10.1016/j.jhep.2023.12.005
  5. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. Journal of Hepatology. 2022;76(4):959-974.  https://doi.org/10.1016/j.jhep.2021.12.022
  6. Reiberger T, Hofer BS. The Baveno VII concept of cirrhosis recompensation. Digestive and Liver Disease. 2023;55(4):431-441.  https://doi.org/10.1016/j.dld.2022.12.014
  7. Feng G, Valenti L, Wong VW, Fouad YM, Yilmaz Y, Kim W, Sebastiani G, Younossi ZM, Hernandez-Gea V, Zheng MH. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology. 2024;21(1):46-56.  https://doi.org/10.1038/s41575-023-00846-4
  8. Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2022;75(5):1235-1246. https://doi.org/10.1002/hep.32204
  9. Hofer BS, Burghart L, Halilbasic E, Simbrunner B, Petrenko O, Mandorfer M, Stättermayer AF, Trauner M, Reiberger T. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis. Alimentary Pharmacology and Therapeutics. 2024;59(8):962-972.  https://doi.org/10.1111/apt.17908
  10. Sharma S, Roy A. Recompensation in Cirrhosis: Current Evidence and Future Directions. Journal of Clinical and Experimental Hepatology. 2023;13(2):329-334.  https://doi.org/10.1016/j.jceh.2022.08.002
  11. Garbuzenko DV. Current strategies for targeted therapy of liver fibrosis. Bjulleten’ sibirskoj mediciny. 2022;21(3):154-165. (In Russ.). https://doi.org/10.20538/1682-0363-2022-3-154-165
  12. Lens S, Baiges A, Alvarado-Tapias E, LLop E, Martinez J, Fortea JI, Ibáñez-Samaniego L, Mariño Z, Rodríguez-Tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, García-Pagán JC, Forns X. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology. 2020;73(6):1415-1424. https://doi.org/10.1016/j.jhep.2020.05.050
  13. Garbuzenko DV. Morphofunctional rearrangement of the hepatic vasculature in the pathogenesis of portal hypertension in liver cirrhosis. Therapeutic Archive. 2014;86(2):90-95. (In Russ.).
  14. Garbuzenko DV. The mechanisms of adaptation of the vascular bed to hemodynamic changes in portal hypertension. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2013;(1):52-57. (In Russ.). https://doi.org/10.15690/vramn.v68i1.538
  15. Garbuzenko DV. Gut microbiota modulation in acute decompensation of liver cirrhosis: theory and therapeutic potential. Russian Journal of Evidence-Based Gastroenterology. 2022;11(4):65-76. (In Russ.). https://doi.org/10.17116/dokgastro20221104165
  16. Ivashkin VT, Mayevskaya MV, Pavlov ChS, Sivolap YuP, Lunkov VD, Zharkova MS, Maslennikov RV. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2017;27(6):20-40. (In Russ.).
  17. Lim WH, Tay P, Ng CH, Tan DJH, Ong C, Koh JH, Teng M, Chee D, Wong ZY, Kawaguchi T, Takahashi H, Muthiah M, Tan EXX, Wijarnpreecha K, Lee GH, Noureddin M, Lee BP, Mathurin P, Loomba R, Huang DQ. Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. Alimentary Pharmacology and Therapeutics. 2024;59(6):730-741.  https://doi.org/10.1111/apt.17888
  18. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, Audano M, Tanno H, Lerner E, Passamonti M. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996;111(3):701-709.  https://doi.org/10.1053/gast.1996.v111.pm8780575
  19. Giard JM, Dodge JL, Terrault NA. Superior Wait-List Outcomes in Patients with Alcohol-Associated Liver Disease Compared With Other Indications for Liver Transplantation. Liver Transplantation. 2019;25(9):1310-1320. https://doi.org/10.1002/lt.25485
  20. Pose E, Torrents A, Reverter E, Perez-Campuzano V, Campos-Varela I, Avitabile E, Gratacós-Ginès J, Castellote J, Castells L, Colmenero J, Tort J, Ginès P, Crespo G. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. Journal of Hepatology. 2021;75(2):275-283.  https://doi.org/10.1016/j.jhep.2021.02.033
  21. Aravinthan AD, Barbas AS, Doyle AC, Tazari M, Sapisochin G, Cattral MS, Ghanekar A, McGilvray ID, Selzner M, Greig PD, Bhat M, Selzner N, Grant DR, Lilly LB, Renner EL. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transplant International. 2017;30(11):1140-1149. https://doi.org/10.1111/tri.13008
  22. Hofer BS, Simbrunner B, Hartl L, Jachs M, Balcar L, Paternostro R, Schwabl P, Semmler G, Scheiner B, Trauner M, Mandorfer M, Reiberger T. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver International. 2023;43(10):2220-2231. https://doi.org/10.1111/liv.15676
  23. Hofer BS, Simbrunner B, Hartl L, Jachs M, Bauer DJM, Balcar L, Paternostro R, Schwabl P, Semmler G, Scheiner B, Staettermayer AF, Trauner M, Mandorfer M, Reiberger T. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis. Clinical Gastroenterology and Hepatology. 2023;21(9):2308-2317. https://doi.org/10.1016/j.cgh.2022.11.033
  24. Garbuzenko DV. The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection. Voprosy virusologii. 2021;66(5):331-339. (In Russ.). https://doi.org/10.36233/0507-4088-70
  25. Wang Q, Zhao H, Deng Y, Zheng H, Xiang H, Nan Y, Hu J, Meng Q, Xu X, Fang J, Xu J, Wang X, You H, Pan CQ, Xie W, Jia J. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. Journal of Hepatology. 2022;77(6):1564-1572. https://doi.org/10.1016/j.jhep.2022.07.037
  26. Kong Y, Lv T, Li M, Zhao L, Meng T, Wu S, Wei W, Zhang Q, Chen S, You H, Lens S, Yoshiji H, Francque S, Tsochatzis E, Sarin SK, Mandorfer M, Jia J; BAVENO Cooperation: an EASL consortium. Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease. Hepatology International. 2022;16(5):1052-1063. https://doi.org/10.1007/s12072-022-10369-w
  27. An J, Park DA, Ko MJ, Ahn SB, Yoo JJ, Jun DW, Yim SY. Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine. 2022;12(9):1517. https://doi.org/10.3390/jpm12091517
  28. Kim TH, Um SH, Lee YS, Yim SY, Jung YK, Seo YS, Kim JH, An H, Yim HJ, Yeon JE, Byun KS. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Alimentary Pharmacology and Therapeutics. 2022;55(1):83-96.  https://doi.org/10.1111/apt.16658
  29. Wen S, Ruan J, Shen J, Wang X, Yang G, Fu J, Li L, Pan X. Development and validation of a nomogram to predict recompensation in HBV-related cirrhosis with ascites as the single first decompensating event. Scandinavian Journal of Gastroenterology. 2023;58(8):915-922.  https://doi.org/10.1080/00365521.2023.2181037
  30. El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, McHutchison J, Brainard DM, Terrault N, Curry MP. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018;154(8):2111-2121. https://doi.org/10.1053/j.gastro.2018.03.022
  31. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O’Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015;149(3):649-659.  https://doi.org/10.1053/j.gastro.2015.05.010
  32. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X; SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infectious Diseases. 2016;16(6):685-697.  https://doi.org/10.1016/S1473-3099(16)00052-9
  33. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. New England Journal of Medicine. 2015;373(27):2618-2628. https://doi.org/10.1056/NEJMoa1512614
  34. Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, Reddy KR, Asselah T, Gane E, Curry MP, Forns X. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. Journal of Viral Hepatitis. 2017;24(10):823-831.  https://doi.org/10.1111/jvh.12706
  35. Nikolaidis N, Vassiliadis T, Giouleme O, Tziomalos K, Grammatikos N, Patsiaoura K, Orfanou-Koumerkeridou E, Balaska A, Eugenidis N. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clinical Transplantation. 2005;19(3):321-326.  https://doi.org/10.1111/j.1399-0012.2005.00340.x
  36. Manolakopoulos S, Triantos C, Theodoropoulos J, Vlachogiannakos J, Kougioumtzan A, Papatheodoridis G, Tzourmakliotis D, Karamanolis D, Burroughs AK, Archimandritis A, Raptis S, Avgerinos A. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. Journal of Hepatology. 2009;51(3):468-474.  https://doi.org/10.1016/j.jhep.2009.05.031
  37. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. Journal of Hepatology. 2010;52(2):176-182.  https://doi.org/10.1016/j.jhep.2009.11.007
  38. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54(1):91-100.  https://doi.org/10.1002/hep.24361
  39. Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, Kim TY, Sohn JH, Tak WY, Han KH. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61(6):1809-1820. https://doi.org/10.1002/hep.27723
  40. Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World Journal of Gastroenterology. 2017;23(13):2396-2403. https://doi.org/10.3748/wjg.v23.i13.2396
  41. Hui VW, Wong GL, Wong VW, Chan HL, Lai JC, Tse YK, Lai MS, Yam TF, Li D, Fan X, Yip TC. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis. JHEP Reports. 2023;5(9):100814. https://doi.org/10.1016/j.jhepr.2023.100814
  42. Zhang Y, Liu X, Li S, Lin C, Ye Q, Wang Y, Wu J, Zhang Y, Gao H, Li T, Qu Y, Wang Y. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria. Hepatology Communications. 2023;8(1):e0355. https://doi.org/10.1097/HC9.0000000000000355
  43. Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy RK, Afdhal NH. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology. 2014;60(Suppl):320A-321A.
  44. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal of Hepatology. 2016;65(3):524-531.  https://doi.org/10.1016/j.jhep.2016.05.010
  45. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K; HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology. 2016;64(6):1224-1231. https://doi.org/10.1016/j.jhep.2016.01.029
  46. Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. Journal of Hepatology. 2016;65(4):692-699.  https://doi.org/10.1016/j.jhep.2016.05.027
  47. Perricone G, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagiuoli S, Belli LS; European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. Liver International. 2018;38(12):2170-2177. https://doi.org/10.1111/liv.13878
  48. Macken L, Gelson W, Priest M, Abouda G, Barclay S, Fraser A, Healy B, Irving W, Verma S. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. Journal of Medical Virology. 2019;91(11):1979-1988. https://doi.org/10.1002/jmv.25552
  49. Moon AM, Green PK, Rockey DC, Berry K, Ioannou GN. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Alimentary Pharmacology and Therapeutics. 2020;51(3):364-373.  https://doi.org/10.1111/apt.15586
  50. Puigvehí M, Londoño MC, Torras X, Lorente S, Vergara M, Morillas RM, Masnou H, Serrano T, Miquel M, Gallego A, Lens S, Carrión JA. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. Journal of Gastroenterology. 2020;55(2):205-216.  https://doi.org/10.1007/s00535-019-01619-0
  51. Liu CH, Chen CY, Su WW, Liu CJ, Lo CC, Huang KJ, Chen JJ, Tseng KC, Chang CY, Peng CY, Shih YL, Huang CS, Kao WY, Yang SS, Tsai MC, Wu JH, Chen PY, Su PY, Hwang JJ, Fang YJ, Lee PL, Tseng CW, Lee FJ, Lai HC, Hsieh TY, Chang CC, Chang CH, Huang YJ, Kao JH. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. Clinical and Molecular Hepatology. 2021;27(4):575-588.  https://doi.org/10.3350/cmh.2021.0155
  52. Tada T, Kurosaki M, Nakamura S, Hasebe C, Kojima Y, Furuta K, Kobashi H, Kimura H, Ogawa C, Yagisawa H, Uchida Y, Joko K, Akahane T, Arai H, Marusawa H, Narita R, Ide Y, Sato T, Kusakabe A, Tsuji K, Mori N, Kondo M, Mitsuda A, Izumi N. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Journal of Medical Virology. 2021;93(11):6247-6256. https://doi.org/10.1002/jmv.27157
  53. Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, Shimizu M, Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. Journal of Gastroenterology. 2021;56(1):67-77.  https://doi.org/10.1007/s00535-020-01733-4
  54. Takaoka Y, Miura K, Morimoto N, Ikegami T, Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H; Liver Investigators in the Northern Kanto Study (LINKS) group. Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatology Research. 2021;51(1):51-61.  https://doi.org/10.1111/hepr.13576
  55. Meunier L, Belkacemi M, Pageaux GP, Radenne S, Vallet-Pichard A, Houssel-Debry P, Duvoux C, Botta-Fridlund D, de Ledinghen V, Conti F, Anty R, Di Martino V, Debette-Gratien M, Leroy V, Gerster T, Lebray P, Alric L, Abergel A, Dumortier J, Besch C, Montialoux H, Samuel D, Duclos-Vallée JC, Coilly A. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years? Viruses. 2022;15(1):137.  https://doi.org/10.3390/v15010137
  56. Su PS, Wu SH, Chu CJ, Su CW, Lin CC, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. Journal of the Chinese Medical Association. 2022;85(2):152-159.  https://doi.org/10.1097/JCMA.0000000000000653
  57. Kotani K, Enomoto M, Uchida-Kobayashi S, Tamori A, Yukawa-Muto Y, Odagiri N, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Kageyama K, Yamamoto A, Yoshida A, Higashiyama S, Kawabe J, Kawada N. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis. Journal of Gastroenterology. 2023;58(4):394-404.  https://doi.org/10.1007/s00535-023-01963-2
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.